Novo unveils new research grant to mark World Haemophilia Day
pharmafile | April 18, 2016 | News story | Medical Communications, Research and Development, Sales and Marketing | Novo Nordisk, grant, haemophilia, hero, world haemophilia day
Novo Nordisk has marked World Haemophilia Day 2016 with the announcement of a new research grant aimed at supporting and encouraging research projects focused on the psychological issues faced by people living with the condition.
The HERO (haemophilia experiences, results, opportunities) research grant is worth up to €75,000 and, as part of the global campaign, Novo is calling on people to take part in spreading the message by using the hashtags #MeetTheHERO and #WHD2016.
Globally, it is estimated that 440,000 people have haemophilia. It is a blood clotting disorder that is characterised by internal bleeding into the joints, muscles, and other tissues can cause severe pain, joint damage, and disability. The HERO study encompasses the psychosocial experiences of people with haemophilia, their families and their health care providers and covers a range of themes.
Paul Huggins, corporate VP at Novo Nordisk, says: “The HERO research grant is part of our commitment to helping people with haemophilia live a life with fewer limitations and support the heroes who care for them.”
Novo’s campaign supports the World Federation of Haemophilia campaign ‘Treatment for all, the vision of all’. The research grant is available to healthcare professionals providing care for people with haemophilia, and social workers or equivalent who provide or have expertise in psychosocial support for people with haemophilia.
Sean Murray
Related Content
Pfizer’s Beqvez approved by FDA for haemophilia B treatment
Pfizer has announced that the US Food and Drug Administration (FDA) has approved Beqvez (fidanacogene …
CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment
Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk …